UPDATE: Jefferies Assumes Arbutus Biopharma (ABUS) at Hold

December 29, 2021 3:51 AM EST
Get Alerts ABUS Hot Sheet
Price: $2.90 -3.65%

Rating Summary:
    7 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 32 | New: 11
Join SI Premium – FREE
(Updated - December 29, 2021 3:51 AM EST)

Jefferies analyst Dennis Ding assumes coverage on Arbutus Biopharma (NASDAQ: ABUS) with a Hold rating and a price target of $4.00.

The analyst comments "We are assuming coverage of ABUS at Hold. ABUS is developing drugs for HepB, and while early data looks promising, functional cure data is years away, and we're uncertain if ABUS's approach would be positive in light of competitor triple combo data. There are more questions than answers at this point, plus investors need to be mindful of litigation noise over the next few years, which could swing the stock (hard to predict)."

For an analyst ratings summary and ratings history on Arbutus Biopharma click here. For more ratings news on Arbutus Biopharma click here.

Shares of Arbutus Biopharma closed at $3.82 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co